Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2002, p. 2743-2750, Vol. 22, No. 8
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.8.2743-2750.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Gregory David,2 Hong Shen-Li,3 Jason Potes,1 Rebecca Muhle,1 Hye-Chun Lee,3 Harry Hou, Jr.,3 Ken Chen,3 and Ronald A. DePinho2*
Department of Pediatrics,1 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461,3 Departments of Adult Oncology, Medicine and Genetics, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 021152
Received 7 November 2001/ Returned for modification 18 December 2001/ Accepted 15 January 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The subsequent identification of the yeast SIN3 mammalian orthologs, Sin3A and Sin3B, and their physical interaction with the Mad family of sequence-specific transcriptional repressors (Mad/Mxi1) supported the view that Mad/Mxi1-mediated transcriptional repression might be executed on the level of chromatin regulation (3, 28). With the identification of the mammalian histone deacetylases HDAC1 and HDAC2 and their significant homology to yeast RPD3 (33, 38), it became apparent that mSin3 functions to tether sequence-specific transcriptional repressors to histone deacetylase activity (1, 12, 13, 16, 20, 40). Biochemical studies with mammalian cells have demonstrated that mSin3 possesses histone deacetylase activity and that this mSin3-associated activity requires physical interaction between HDAC1 and the C-terminal region of mSin3. The mSin3/HDAC1 interaction appears to be indirect as determined by the presence of mSin3 and HDAC1 in reciprocal immunoprecipitations in vivo but not in vitro.
More recent studies with yeast have identified another integral component of the Sin3-Rpd3 complex, the Sds3 transcriptional repressor (6, 17). These studies demonstrated that Sds3 maintains the physical integrity of the Sin3-Rpd3 complex and is required for its histone deacetylase activity (17). These biochemical observations gain added significance in light of the fact that yeast SDS3, SIN3, and RPD3 all emerged from a genetic screen aimed at identifying suppressors of a silencing defective rap1 mutant (34). Further evidence for a genetic and functional link between Sds3 and Sin3-Rpd3 came from finding that sds3 null mutants demonstrated substantial phenotypic overlap with strains mutant for sin3 and/or rpd3 (6, 34, 35).
The C-terminal region of mSin3 that is required for HDAC1 interaction, designated the histone deacetylase interaction domain (HID), plays an essential role in Sin3-mediated repression of both gene expression and Myc-mediated cellular transformation (1, 16). In an effort to understand better the role of the mSin3 HID, we sought to identify factors that may participate in the critical physical and functional interactions between mSin3 and HDAC1. Here, we report the identification of a component of the mSin3-HDAC1 complex that bears striking homology to the previously identified yeast Sds3, designated mSds3. Although mSds3 does not possess intrinsic histone deacetylase activity, mSds3 represses transcription in reporter assays, recruits histone deacetylase activity, and supports the catalytic activity of HDAC1 in a manner analogous to its ortholog in yeast.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Immunoprecipitation and Western blot. Subconfluent 293T or NIH 3T3 cells were transfected with 3 µg of each of the appropriate expression constructs and 30 µg of Lipofectamine reagent (Gibco). Where indicated, cells were metabolically labeled using [35S]methionine (Amersham) for 6 h prior to harvest. Mouse Sds3 rabbit polyclonal antibody was raised against glutathione-S-transferase (GST)-mSds3 fusion protein encoding residues 1 to 110 of mSds3 and affinity purified (Research Genetics). Immunoprecipitations and Western blotting of overexpressed proteins were performed as described previously (1) using anti-FLAG M2 (Sigma), anti-mSin3B (PAH2) (Santa Cruz Biotechnology), anti-HDAC1 (Upstate Biotechnology), and anti-mSds3 antibodies. For interaction studies of endogenous proteins, newborn (1- to 3-day-old) C57/B6J (Jackson Labs) mouse tissues were isolated and homogenized in lysis buffer, and 1 to 5 mg of protein was used per immunoprecipitation with normal rabbit serum (Santa Cruz Biotechnology), anti-mSin3A (PAH2) (Santa Cruz Biotechnology), anti-HDAC1 (Upstate Biotechnology), or anti-mSds3 antibodies, as described above.
Deacetylase assays. A peptide encoding for the 24 first amino acids of histone H4 was synthesized, 3H radiolabeled, and purified. Immunoprecipitates were incubated for 2 h at 37°C, and deacetylase activity was determined as described previously (33).
In vitro translation and GST pull-down assays.
The GST fusion constructs were generated by fusing full-length mSds3 or HDAC1 cDNAs in-frame into pGEX (Pharmacia). GST protein was expressed in DH5
or BL21 cells and purified with glutathione-Sepharose beads (Pharmacia). Plasmid encoding full-length SMRT was kindly provided by R. M. Evans, and plasmids encoding full-length RbAp48 and HDAC1 were kindly provided by S. L. Schreiber. Radiolabeled TNT-coupled transcription and translation products (Promega) were incubated with GST protein for 1 h at 4°C in radioimmunoprecipitation buffer.
Reporter assays. Subconfluent NIH 3T3 cells were transfected with various GAL4-mSds3 fusion constructs or GAL4-mSin3B and the luciferase reporter plasmid containing four GAL4 binding sites upstream of the myelomonocytic growth factor minimal promoter (2), kindly provided by R. N. Eisenman. Trypticase soy agar (TSA) (100 ng/ml) (Sigma) was added for 24 h prior to lysis. Cells were lysed in luciferase lysis buffer (Invitrogen) 48 h posttransfection. Cell extracts were assayed for luciferase activity using luciferase buffer (Invitrogen) and an automated luminometer. Transfection efficiencies were normalized using an internal ß-galactosidase control.
RNA interference assays. RNA oligonucleotides that were 21 bases in length were synthesized by Dharmacon. The first [RNAi(1)] and second [RNAi(2)] sets of complementary primers correspond, respectively, to nucleotides 127 to 145 and 306 to 324 of the mSds3 cDNA sequence relative to the first nucleotide of the start codon. Deoxyribosylthymidines were added 3' of each primer. Each primer was diluted to 20 µM and annealed with its complementary primer as described (8). Oligofectamine (Life Technology) was used to transfect double-stranded RNA, and Lipofectamine Plus was used to transfect plasmids according to the manufacturer's instructions. The cells were lysed 60 h after transfection, and histone deacetylase assays were performed on 500 µg of protein.
| RESULTS |
|---|
|
|
|---|
|
|
383-550) abolished interaction with mSds3FLAG (Fig. 3b, lanes 1 and 2) as well as interaction with the polypeptides migrating at 60 and 58 kDa, and at 48 and 46 kDa, that are consistent in size with HDAC1 and HDAC2 and with RbAp48 and RbAp46, respectively (Fig. 3b, compare lanes 1 and 3). Notably, helix-breaking proline substitutions in PAH3 and PAH4 of mSin3B did not affect mSin3B-mSds3 interaction (data not shown). Anti-FLAG immunoprecipitates of mSds3
SIDFLAG (
188-226) did not possess detectable amounts of mSin3B or of polypeptides corresponding in size to HDAC1/2 or RbAp46/48 (Fig. 3b, lanes 3 and 4). An analysis of various newborn mouse tissues revealed endogenous mSds3-mSin3A complexes as evidenced by the presence of mSin3A in anti-Sds3 immunoprecipates, and correspondingly, mSds3 in the anti-mSin3A immunoprecipitates (Fig. 3c). Together, these results indicate that mSds3 interacts with mSin3 proteins in vitro and in vivo .
|
SID indicates that homodimerization is mSin3 independent (Fig. 4a). Consistent with these yeast-based assays, coimmunoprecipitation studies with mammalian cells revealed the capacity of the mSds3 N-terminal region (residues 1 to 187) to engage FLAG-tagged full-length mSds3 (Fig. 4b). Additionally, GST-mSds3 bound in vitro-translated mSds3 (Fig. 4c), indicating that while higher order complexes are likely to form in vivo, homodimerization of mSds3 seems to occur via direct protein-protein interaction.
|
|
383-550) that is unable to bind mSds3 also failed to bind HDAC1 (lane 4), indicating that the integrity of this region of mSin3B is essential for interaction with both mSds3 and HDAC1. Together, these results suggest that despite the use of operationally defined HID of mSin3B, mSds3 and HDAC1 do not compete for the same site within the HID. Given that mSin3B can associate with both HDAC1 and mSds3, the role of mSin3B in the interaction between mSds3 and HDAC1 was investigated. To this end, 293T cells were transfected with mSin3BFLAG and/or HDAC1FLAG, and their presence in endogenous anti-mSds3 immunoprecipitates was analyzed. In separate transfections, anti-mSds3 immunoprecipitates contained mSin3BFLAG, as expected (Fig. 5c, lane 5), but only modest amounts of HDAC1FLAG. Interestingly, the amount of HDAC1FLAG in anti-mSds3 immunoprecipitates was significantly increased by overexpression of mSin3BFLAG (Fig. 5c, compare lane 4 to lane 6). Together, these results strongly suggest that mSin3B, HDAC1, and mSds3 are part of the same complex in vivo and that mSin3B and mSds3 cooperate to stabilize the interaction with HDAC1.
mSds3 represses transcription and augments histone deacetylase activity of HDAC1 in vivo. To determine whether mSds3 recruits histone deacetylase activity, histone deacetylase assays were performed on anti-mSds3 immunoprecipitates in three independent experiments. mSds3 immunoprecipitates from untransfected NIH 3T3 cells contained a modest but reproducible deacetylase activity above background levels (Fig. 6a, lane 3; P = 0.005). Similarly, reproducible deacetylase activity was detected in anti-FLAG immunoprecipitates of 293T cells transfected with mSds3FLAG, and this activity was enhanced by mSin3B overexpression (Fig. 6b, compare lanes 4 and 6), consistent with the physical interaction data presented in Fig. 5c above. Deacetylase activity above background levels was not detected in immunoprecipitates of the mSds3 mutant that is unable to bind mSin3B (lane 5), and the activity of this mSds3 mutant was not altered by mSin3B overexpression (lane 7). Taken together, these results are consistent with the view that mSds3 does not possess intrinsic deacetylase activity but instead functions to recruit HDAC catalytic activity in a manner that is augmented by mSin3B.
|
The addition of TSA, a potent inhibitor of histone deacetylase activity, only partly reduced the repressive activity driven by mSds3 (Fig. 6c). This reduction was only 35% for GAL-mSds3 compared to 70% for GAL-mSin3B. As expected, TSA affected the repression activity of the mutants of mSds3 which were able to bind to mSin3, and therefore HDAC1, whereas repression was unchanged for those mutants that did not bind to mSin3/HDAC1. Western blot analysis of cell lysates following transient transfection of the various GAL4-mSds3 fusions demonstrated equivalent expression levels (data not shown). Together, these results suggest that mSds3 brings both HDAC-dependent and -independent repressive activity to the mSin3/HDAC complex.
Next, we sought to determine whether the mSds3, like its yeast counterpart, played a role in supporting the catalytic activity of the histone deacetylase molecule. The RNA interference method was used to assess the impact of reduced mSds3 levels on HDAC1 enzymatic activity. We generated two sets of cRNA primers corresponding to nucleotides 127 to 145 [RNAi(1)] or to nucleotides 306 to 324 [RNAi(2)] of the mSds3 cDNA. The efficiency of these double-stranded RNAs in down-regulating the level of mSds3 protein was tested on lysates of NIH 3T3 cells expressing a small amount of mSds3FLAG protein. Indeed, transfection of RNAi(2) efficiently down-regulated the level of exogenous mSds3, while mock transfection or transfection with RNAi(1) did not affect the level of exogenously expressed mSds3 (Fig. 7a). This result correlates with previous observations showing that RNAi are far more efficient when the 5' nucleotide sequence is AA, as is the case for RNAi(2) (T. Tuschl, personal communication).
|
| DISCUSSION |
|---|
|
|
|---|
Beyond its role in promoting a functional HDAC1 activity in the mSin3 complex, the precise mechanism(s) through which mSds3 operates in not yet clear. When tethered to DNA, mSds3 exhibits potent transcriptional repression activity in reporter assays, and this activity is only partly neutralized by the HDAC inhibitor, TSA, or by deletion of the putative SID of mSds3. Thus, it is possible that mSds3 might recruit activities other than histone deacetylase. Within the context of the mSin3 complex, the additional finding that mSds3 can homodimerize raises the intriguing possibility that mSds3 might allows for the assembly of a large complex composed of two Sin3 molecules, each with distinct repressor activities. Although this supposition remains unproven, it is notable that yeast Sin3p is present in a large multiprotein complex with an apparent molecular mass of greater than 2 million Da (14).
In RNAi-mediated knock-down experiments, HDAC1 activity was markedly impaired in vivo. This observation, coupled with mSin3B-driven enhancement of the mSds3/HDAC1 interaction, suggests that these three proteins act cooperatively to maintain the catalytic activity of the complex. Correspondingly, it is possible that the basis for the catalytically inactive nature of HDAC1 generated in bacterial or insect cells (41; G. David and R. A. DePinho, unpublished results) relates to the absence of mSds3-like factors. These observations are reminiscent of several studies emphasizing an essential role of SANT domain-containing proteins in histone deacetylase activity (the SANT domain is a putative DNA-binding domain in SWI3, ADA2, NCoR, and TFIIB). Specifically, Zhang et al. (41) reported that the formation of a catalytically active NuRD complex requires the presence of the SANT domain protein MTA2. Similarly, SMRT and NCoR, which also contain SANT domains, are necessary for catalytically active HDAC3 (10). Finally, the CoREST protein, which is a core component of an mSin3-independent HDAC1/2 complex, possesses two SANT domains (39). With regard to the mSin3/HDAC complex, SANT domain-containing proteins have not yet been identified and it is plausible that mSds3 may function to recruit such a protein to the Sin3/HDAC complex.
Current database searches have not identified highly related mSds3 homologs, although two mammalian proteins share some relatedness. Brms1, identified previously as a breast cancer metastatic suppressor gene (30), shares 24% identity and 50% similarity with more than half of the mSds3 protein sequence (mSds3 residues 62 to 232), including the putative SID domain. A second mammalian protein (human MGC11296) whose function has not yet been characterized also shares homology to mSds3 and to a higher extent to Brms1. This protein contains an additional C-terminal portion that is absent from brms1 but that shares homology to mSds3 (residues 232 to 323 in mSds3). Together, these findings raise the possibility of the existence of a family of mammalian mSds3-related proteins, which, like mSds3, might play a role in mSin3-related complexes.
Several lines of evidence point to a potential role for mSds3 in tumor suppressor pathways. First, Mxi1, a member of the Mad family of transcriptional repressors, functions as a bona fide tumor suppressor as evidenced by a cancer predisposition in mice null for Mxi1 (29) and a possible linkage to the pathogenesis of prostate cancer in humans (7, 25). Similarly, cell culture-based transformation assays have established that recruitment of the mSin3 complex is essential to Mxi1's antioncogenic actions (1, 26). Second, there is an emerging role of histone deacetylases in the development of hematopoietic malignancies (4, 5, 9, 11, 18, 19), and HDAC inhibitors have exhibited therapeutic activity in the clinic (for a review, see reference 23). Third, as noted above, mSds3 bears structural relatedness to a putative metastases suppressor gene, Brms1 (30). Finally, using computational analysis, we localized the gene encoding human SDS3 on chromosome 12q24.2, a region known to be deleted in 25% (4 of 16) of cases of human prostate cancer (27). Given the requirement of an active mSin3/HDAC complex for Mxi1 to function as a tumor suppressor, it is tempting to speculate that mSds3 may be an important component of the Mxi1-mSin3-HDAC1 tumor suppressor pathway. An improved understanding of the regulation of histone deacetylase activity by mSds3 might allow the identification of novel avenues for modulation of HDAC activity. Histone deacetylase inhibitors have shown promise in the treatment of hematologic malignancies, but their utility has been limited by toxicity and short-term efficacy (22). Future studies into the mechanisms by which mSds3 regulates the catalytic activity of HDAC might augment the therapeutic impact of these deacetylase inhibitor programs.
| ACKNOWLEDGMENTS |
|---|
We thank Thomas Graf, Nicole Schreiber-Agus, and Nabeel Bardeesy for helpful discussions, Maria Dudas and Carlos Cordon-Cardo for providing mouse embryo sections, and Annick Harel-Bellan for advice on histone deacetylase assays. We also thank Jim DeCaprio and Richard Maser for critical reading of the manuscript.
This work was supported by NIH grant K11CA68266 (L.A. and R.A.D.), the Ruth Estrin Goldberg Memorial Award (L.A.), an American Cancer Society Young Investigator Award (L.A.), and Human Frontier Science Program Organization (G.D.). R.A.D. is an American Cancer Society Research Professor.
| FOOTNOTES |
|---|
Present address: Schering-Plough Research Institute, Kenilworth, NJ 07033. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Ayer, D. E., C. D. Laherty, Q. A. Lawrence, A. P. Armstrong, and R. N. Eisenman. 1996. Mad proteins contain a dominant transcription repression domain. Mol. Cell. Biol. 16:5772-5781.[Abstract]
3. Ayer, D. E., Q. A. Lawrence, and R. N. Eisenman. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776.[CrossRef][Medline]
4. David, G., L. Alland, S. H. Hong, C. W. Wong, R. A. DePinho, and A. Dejean. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549-2556.[CrossRef][Medline]
5.
Dhordain, P., O. Albagli, R. J. Lin, S. Ansieau, S. Quief, A. Leutz, J. P. Kerckaert, R. M. Evans, and D. Leprince. 1997. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc. Natl. Acad. Sci. USA 94:10762-10767.
6.
Dorland, S., M. L. Deegenaars, and D. J. Stillman. 2000. Roles for the Saccharomyces cerevisiae SDS3, CBK1 and HYM1 genes in transcriptional repression by SIN3. Genetics 154:573-586.
7. Eagle, L. R., X. Yin, A. R. Brothman, B. J. Williams, N. B. Atkin, and E. V. Prochownik. 1995. Mutation of the MXI1 gene in prostate cancer. Nat. Genet. 9:249-255.[CrossRef][Medline]
8. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.[CrossRef][Medline]
9. Grignani, F., S. De Matteis, C. Nervi, L. Tomassoni, V. Gelmetti, M. Cioce, M. Fanelli, M. Ruthardt, F. F. Ferrara, I. Zamir, C. Seiser, M. A. Lazar, S. Minucci, and P. G. Pelicci. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818.[CrossRef][Medline]
10. Guenther, M. G., O. Barak, and M. A. Lazar. 2001. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21:6091-6101.
11.
Guidez, F., S. Ivins, J. Zhu, M. Soderstrom, S. Waxman, and A. Zelent. 1998. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634-2642.
12. Hassig, C. A., T. C. Fleischer, A. N. Billin, S. L. Schreiber, and D. E. Ayer. 1997. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341-347.[CrossRef][Medline]
13. Heinzel, T., R. M. Lavinsky, T. M. Mullen, M. Soderstrom, C. D. Laherty, J. Torchia, W. M. Yang, G. Brard, S. D. Ngo, J. R. Davie, E. Seto, R. N. Eisenman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48.[CrossRef][Medline]
14. Kasten, M. M., S. Dorland, and D. J. Stillman. 1997. A large protein complex containing the yeast Sin3p and Rpd3p transcriptional regulators. Mol. Cell. Biol. 17:4852-4858.[Abstract]
15.
Kingston, R. E., and G. J. Narlikar. 1999. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 13:2339-2352.
16. Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, and R. N. Eisenman. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356.[CrossRef][Medline]
17.
Lechner, T., M. J. Carrozza, Y. Yu, P. A. Grant, A. Eberharter, D. Vannier, G. Brosch, D. J. Stillman, D. Shore, and J. L. Workman. 2000. Sds3 (suppressor of defective silencing 3) is an integral component of the yeast Sin3·Rpd3 histone deacetylase complex and is required for histone deacetylase activity. J. Biol. Chem. 275:40961-40966.
18. Lin, R. J., L. Nagy, S. Inoue, W. Shao, W. H. Miller, Jr., and R. M. Evans. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814.[CrossRef][Medline]
19.
Melnick, A. M., J. J. Westendorf, A. Polinger, G. W. Carlile, S. Arai, H. J. Ball, B. Lutterbach, S. W. Hiebert, and J. D. Licht. 2000. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol. Cell. Biol. 20:2075-2086.
20. Nagy, L., H. Y. Kao, D. Chakravarti, R. J. Lin, C. A. Hassig, D. E. Ayer, S. L. Schreiber, and R. M. Evans. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380.[CrossRef][Medline]
21. Nasmyth, K., D. Stillman, and D. Kipling. 1987. Both positive and negative regulators of HO transcription are required for mother-cell-specific mating-type switching in yeast. Cell 48:579-587.[CrossRef][Medline]
22. Newmark, H. L., J. R. Lupton, and C. W. Young. 1994. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 78:1-5.[CrossRef][Medline]
23. Pandolfi, P. P. 2001. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 48(Suppl. 1):S17-S19.
24. Parthun, M. R., J. Widom, and D. E. Gottschling. 1996. The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 87:85-94.[CrossRef][Medline]
25. Prochownik, E. V., L. Eagle Grove, D. Deubler, X. L. Zhu, R. A. Stephenson, L. R. Rohr, X. Yin, and A. R. Brothman. 1998. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 22:295-304.[CrossRef][Medline]
26. Rao, G., L. Alland, P. Guida, N. Schreiber-Agus, K. Chen, L. Chin, J. M. Rochelle, M. F. Seldin, A. I. Skoultchi, and R. A. DePinho. 1996. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1. Oncogene 12:1165-1172.[Medline]
27. Sattler, H. P., V. Rohde, H. Bonkhoff, T. Zwergel, and B. Wullich. 1999. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39:79-86.[CrossRef][Medline]
28. Schreiber-Agus, N., L. Chin, K. Chen, R. Torres, G. Rao, P. Guida, A. I. Skoultchi, and R. A. DePinho. 1995. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786.[CrossRef][Medline]
29. Schreiber-Agus, N., Y. Meng, T. Hoang, H. Hou, Jr., K. Chen, R. Greenberg, C. Cordon-Cardo, H. W. Lee, and R. A. DePinho. 1998. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393:483-487.[CrossRef][Medline]
30.
Seraj, M. J., R. S. Samant, M. F. Verderame, and D. R. Welch. 2000. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60:2764-2769.
31.
Smith, R. F., B. A. Wiese, M. K. Wojzynski, D. B. Davison, and K. C. Worley. 1996. BCM Search Launcher-an integrated interface to molecular biology data base search and analysis services available on the World Wide Web. Genome Res. 6:454-462.
32. Stillman, D. J., S. Dorland, and Y. Yu. 1994. Epistasis analysis of suppressor mutations that allow HO expression in the absence of the yeast SW15 transcriptional activator. Genetics 136:781-788.[Abstract]
33. Taunton, J., C. A. Hassig, and S. L. Schreiber. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411.[Abstract]
34. Vannier, D., D. Balderes, and D. Shore. 1996. Evidence that the transcriptional regulators SIN3 and RPD3, and a novel gene (SDS3) with similar functions, are involved in transcriptional silencing in S. cerevisiae. Genetics 144:1343-1353.
35. Vannier, D., P. Damay, and D. Shore. 2001. A role for Sds3p, a component of the Rpd3p/Sin3p deacetylase complex, in maintaining cellular integrity in Saccharomyces cerevisiae. Mol. Genet. Genomics 265:560-568.[CrossRef][Medline]
36. Verreault, A., P. D. Kaufman, R. Kobayashi, and B. Stillman. 1996. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell 87:95-104.[CrossRef][Medline]
37. Vojtek, A. B., S. M. Hollenberg, and J. A. Cooper. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214.[CrossRef][Medline]
38.
Yang, W. M., C. Inouye, Y. Zeng, D. Bearss, and E. Seto. 1996. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl. Acad. Sci. USA 93:12845-12850.
39.
You, A., J. K. Tong, C. M. Grozinger, and S. L. Schreiber. 2001. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc. Natl. Acad. Sci. USA 98:1454-1458.
40. Zhang, Y., R. Iratni, H. Erdjument-Bromage, P. Tempst, and D. Reinberg. 1997. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 89:357-364.[CrossRef][Medline]
41.
Zhang, Y., H. H. Ng, H. Erdjument-Bromage, P. Tempst, A. Bird, and D. Reinberg. 1999. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13:1924-1935.
42. Zhang, Y., Z. W. Sun, R. Iratni, H. Erdjument-Bromage, P. Tempst, M. Hampsey, and D. Reinberg. 1998. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol. Cell 1:1021-1031.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|